No Data
No Data
HKEX Live | WuXi Biologics and Shanghai Allist Pharmaceuticals Co., Ltd. collaborate to conduct clinical research on combination therapy for advanced non-small cell lung cancer, and How Yu-B (02256) surges more than 8% in the afternoon.
Wah Yuet Group B (02256) rose more than 8% in the afternoon. As of press time, it has risen 7.14% to HKD 3.45 with a turnover of HKD 3.1682 million.
With EPS Growth And More, Shanghai Allist Pharmaceuticals (SHSE:688578) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Alice (688578.SH) 2023 equity distribution: $0.40 per share, share registration on May 30
According to Zhitong Finance App News, Alice (688578.SH) issued the 2023 equity distribution implementation notice. The profit distribution is based on the company's total share capital before implementation of the plan, with a cash dividend of 0.40 yuan (tax included) per share. The share registration date is May 30, 2024, and the exclusion (interest) date is May 31, 2024.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Top Owners Are Private Companies With 44% Stake, While 28% Is Held by Individual Investors
Key Insights Shanghai Allist Pharmaceuticals' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 51% of the business is hel
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination With Shanghai Allist's Furmonertinib
Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said its investigational non-small cell lung cancer drug ABSK043 would be clinically tested in combination with Furmonertinib Mesilate Tablets, acco
Heyu-B (02256.HK): Carrying out clinical research on ABSK043 combined with vometinib mesylate tablets to treat advanced non-small cell lung cancer
On May 9, Ge Longhui (02256.HK) announced that ABSK043, an oral small molecule PD-L1 inhibitor developed by it, will soon conduct clinical research on combination treatment for advanced non-small cell lung cancer with vometinib mesylate tablets (trade name: Avsha, “vometinib”) independently developed by Allis (688578.SH).
No Data